184
Results-
Press ReleaseWorldwide premiere : Pierre Fabre launches the Green Impact IndexCreated on : - Last modified on :The first rating tool which, through grades of A, B, C, or D, can be used to measure, improve and communicate information on the environmental and societal impact of cosmetics and family health products, based on a methodology which has been validated and endorsed by AFNOR certification.
-
Press ReleaseAtara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (tab-cel®)Created on : - Last modified on :Pierre Fabre to Commercialize Tab-cel® for Epstein-Barr Virus (EBV)-Positive Cancers in Europe, Middle East, Africa, and Other Select Emerging Markets Atara to Receive Upfront Payment of USD 45 Million, and Up to Approximately USD 320 Million in Total Milestones, Plus Significant Double-digit Tiered Royalties as a Percentage of Net Sales Atara Retains Full Commercialization Rights to Tab-cel® in the United States and Other Major Markets
-
Press ReleasePierre Fabre and the EspeRare Foundation start the EDELIFE clinical trial of a prenatal treatment for a rare genetic disease, XLHEDCreated on : - Last modified on :Geneva, Switzerland, Castres, France (November 15, 2021) – The EspeRare Foundation and the Pierre Fabre group announced today the start of the EDELIFE clinical trial aimed at confirming the safety and efficacy of ER004, a prenatal treatment for XLHED (X-linked Hypohidrotic Ectodermal Dysplasia), a rare and debilitating congenital disease. If positive, the study could lead to the first approved treatment for XLHED by 2026.
-
Press ReleaseAglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncologyCreated on : - Last modified on :Villejuif and Castres, France, November 18th, 2021 – Ribonexus (previously Aglaia Therapeutics), a biotechnology startup developing promising new therapies that can overcome resistance to current targeted therapies in cancer patients, and French pharmaceutical group Pierre Fabre today announce the signing of an exclusive license agreement on a series of Pierre Fabre patented small molecules targeting the Eukaryotic translation initiation factor 4A (eIF4A).
-
Press ReleaseThe SAFE study covered 7 countries and found that people are not paying proper attention to sun protection adviceCreated on : - Last modified on :May is Skin Cancer Detection and Prevention Awareness Month EADV Spring Symposium - May 12–14, 2022. Pierre Fabre Laboratories maintain their commitment to fighting skin cancer: the SAFE study covered 7 countries and found that people are not paying proper attention to sun protection advice.
-
Press ReleaseChanges within the Group Executive CommitteeCreated on : - Last modified on :Castres, 21 September, 2022 - On October 1, Mr. Frédéric Ennabli will be appointed President of the Dermo-Cosmetics & Personal Care Business Unit. As such, Frédéric Ennabli will join the Group’s Executive Committee and will report Mr. Éric Ducournau, Pierre Fabre Group CEO and Pierre Fabre Dermo-Cosmetics CEO. On the same day, Dr. Núria Perez-Cullell will be appointed Vice President of the Medical Affairs and Patient & Consumer Relations department, reporting to Mr. Éric Ducournau, Group CEO.
-
Press ReleasePierre Fabre is taking a minority stake in Gennisium PharmaCreated on : - Last modified on :Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company specializing in medicines for premature newborns and niche markets.
-
Press ReleaseCreation of the Green Impact Index ConsortiumCreated on : - Last modified on :25 economic actors representing more than 1,000 companies join forces to develop an Environmental and Social Impact Labelling Scheme for cosmetic and well-being products.
-
Press ReleaseRARE DISEASE DAY – February 28th, 2023Created on : - Last modified on :Pierre Fabre pursues its commitment against rare diseases in the pediatric, oncology and dermatology fields. The diseases are rare, but they impact a lot of people : nearly 300 million people are affected worldwide1.
-
Press ReleasePIERRE FABRE INAUGURATES ITS NEW INNOVATION CENTER IN CHINACreated on : - Last modified on :Shanghai, Castres, June 9, 2023 – After France, Japon and Brazil, Pierre Fabre has just inaugurated its new dermo-cosmetics innovation and research center in China: “Pierre Fabre China Innovation Center”. The CIC is based in Shanghai, in the district of Pudong, the nerve center of new technologies and research.
We take care of life by designing and developing innovative solutions inspired by consumers and patients, and contributing to the well-being of everyone from health to beauty.